EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults

Christian Leli iD, Lidia Ferrara iD, Paolo Bottino iD, Cristina Bara, Iacopo Megna iD, Serena Penpa, Enrico Felici, Antonio Maconi iD, Andrea Rocchetti

Viruses · 2023

DOI: 10.3390/v16010041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Christian Leli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Virology Laboratory, A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To carry out effective and quick identification of SARS-CoV-2 from nasopharyngeal swabs and contain outbreaks, reliable and rapid tools are needed. Herein, we compared a rapid antigen test based on active microfluidic technology to an RT-qPCR assay in pediatric and young adult patients admitted to the Pediatric Emergency Unit of a Children’s Hospital. Nasopharyngeal swabs collected from patients with suspected COVID-19 disease and from those without COVID-19 related symptoms, but requiring hospitalization, were performed with both antigen test and RT-qPCR assays. We included 375 patients with a median age of 5 years in the study, with an estimated overall prevalence of 7.2%. Overall, we observed a specificity of 97.4% (95% CI: 94.9–98.7) and a sensitivity of 66.6% (95% CI: 46.0–82.7) with a positive likelihood ratio (LR+) of 25.8 (95% CI: 12.8–51.8). In the subgroup of symptomatic patients, the specificity and the sensitivity were 95.2% (95% CI: 89.4–98.0) and 80.0% (95% CI: 44.2–96.5) respectively; LR+ was 16.6 (95% CI: 7.19–38.6). In the asymptomatic subset, the performance showed a specificity of 98.7% (95% CI: 95.8–99.7), a sensitivity of 58.8% (95% CI: 33.5–80.6), and an LR+ of 43.7 (95% CI: 13.3–144.0). Compared to RT-qPCR, the new microfluidic-based antigen test showed higher specificity (>95%) in the pediatric population, thus representing a suitable point-of-care testing (POCT) in a clinical setting with low prevalence of COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansChildYoung AdultChild, PreschoolMicrofluidicsAntigens, ViralTechnologyImmunoassay

Stichwörter der Autor:innen

COVID-19POCTSARS-CoV-2microfluidicpediatric emergency medicine

Substanzen

Antigens, Viral

Autor:innen und Institutionen

  • Microbiology and Virology Laboratory, A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy.
  • Research and Innovation Department (DAIRI), A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy.
  • Pediatric and Pediatric Emergency Unit, A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy.

ORCID-Profile: Christian Leli, Lidia Ferrara, Paolo Bottino, Iacopo Megna, Antonio Maconi

Zitieren

APA

Leli, C., Ferrara, L., Bottino, P., Bara, C., Megna, I., Penpa, S., Felici, E., Maconi, A., & Rocchetti, A. (2023). Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults. Viruses. https://doi.org/10.3390/v16010041

Vancouver

Leli C, Ferrara L, Bottino P, Bara C, Megna I, Penpa S, et al. Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults. Viruses. 2023. doi:10.3390/v16010041

BibTeX
@article{Leli2023,
  author = {Leli, Christian and Ferrara, Lidia and Bottino, Paolo and Bara, Cristina and Megna, Iacopo and Penpa, Serena and Felici, Enrico and Maconi, Antonio and Rocchetti, Andrea},
  title = {Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v16010041}
}
Kostenlos starten →